1 / 40

Multiple Endocrine Neoplasia (MEN) I

Multiple Endocrine Neoplasia (MEN) I. Case Presentation. 62 y/o Female Pmhx - HTN & Cholecystectomy for biliary colic (1995) Presents to OSH for abd pain, N/V. Afeb, mild right sided abd tenderness. Elevated LFTs.

vahe
Download Presentation

Multiple Endocrine Neoplasia (MEN) I

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Multiple Endocrine Neoplasia (MEN) I

  2. Case Presentation 62 y/o Female • Pmhx - HTN & Cholecystectomy for biliary colic (1995) • Presents to OSH for abd pain, N/V. Afeb, mild right sided abd tenderness. Elevated LFTs. • ERCP performed for presumed retained stone – sphincterotomy w/ stent placement. • Post ERCP cont abd pain & developed MI

  3. Transferred to MSH for cardiac cath/stent • post – cath cont abd pain – GI workup begun • 9/4 CT …

  4. Biochemical w/u for pheochromocytoma found to be neg (nl urine catecholamines & nl normetanephrine / metanephrine) • Biochemical w/u for poss neuroendocrine pancreatic lesion – gastrin mild elev. (172/111); mild elev. chromogranin A (38/18); nl glucagon • Pt also at this time reported FMHx of multiglandular hyperparathyroid in mother; labs drawn –hypercalcemic, elevated PTH; elevated prolactin • Head CT negative – pt not candidate for MR (metal stent)

  5. 9/9 SBS negative • 9/11 & 9/12 Capsule endoscopy performed – capsule held up in antrum of stomach – EGD removal of capsule and placement of second capsule in duodenum • Surgery consulted – N/V; Afeb normal VS; lower abdominal tenderness, nl lactate, mild levated WBC (12-13) • 9/14 repeat CT showed

  6. metallic density in RLQ – capsule; cont wall thickening • 9/17 Pt to OR for Small bowel resection/retrieval of capsule

  7. Pathology – Segment of sm bowel w/ ischemic necrosis & carcinoid tumor (1cm) extending into muscularis propria

  8. MULTIPLE ENDOCRINE NEOPLASIA: MEN I SYNDROME

  9. Contents • 1. Parathyroid disease • 2. Anterior Pituitary Adenomas • 3. Entero-pancreatic tumors: Insulinomas Gastrinomas Glucagonomas VIPomas Somatostatinomas Pancreatic Polypeptide-Producing tumors Rare Islet Cell tumors Surgical Therapy • 4. Other tumors

  10. What is MEN–1 ? • AD disorder on chromosome 11 • Consensus recommends that MEN- 1 defined as 2/3 main MEN-1 tumor types • Familial MEN-1 is at least one MEN-1case plus first degree relative w/ 1/3 tumors

  11. Primary Hyperparathyroidism • ~ 100% penetrance – earliest / most common manifestation • 1-2 % all hyperparathyroidism is MEN-1 • Multiglandular involvement (unlike sporadic hyperPTH w/ single gland adenoma) Diagnosing: • Clinically - Stones, bones, groans, mental overtones • Diagnosis – Biochemical =hypercalcemia w/ hi serum PTH • Imaging – sestamibi & bone densitometry

  12. Primary Hyperparathyroidism • Indications for surgery: • Symptomatic or marked hypercalcemia • Nephrolithiasis • Diminished bone density / osteopenia • ** Presence of severe gastric ulcers 20 to gastrinoma (hypercalcemia inc release of gastrin & worsens hypergastrinemia and parathyroidectomy reduces gastrin secretion** -- however PPI’s work well

  13. Therapy for Primary Hyperparathyroidism • Subtotal parathyroidectomy (removal of 3.5) with transcervical near-total prophylactic thymectomy • Parathyroid remnants in situ OR autograft implanted into forearm • Endoscopic parathyroidectomy not appropriate b/c difficulty in identifying all four glands

  14. Primary Hyperparathyroidism (cont) Complications of Parathyroid Surgery: • Temporary hypocalcemia common • 4% risk permanent hypoPTH, 30% risk persistent/recurrent hyperPTH • Graft function successful in >90% of autotransplantations • High rate of recurrence after successful surgical therapy unlike sporadic 67% @ 8yrs

  15. Anterior Pituitary tumors • Prevalence in MEN-1 ranges 15-60% in different series • First clinical manifestation in up 25% of cases • Two-thirds are microadenomas (<1cm) • Prolactinomas 60%, somatotrophinomas 20%, corticotrophinomas and null cell tumors 15% • Pt p/w sx of amenorrhea, galactorrhea, infertility, impotence in men; acromegaly or cushing’s disease • Monitor PRL, IGF-1 • CT/MRI • Trans-sphenoidal resection of pituitary tumor

  16. Entero-pancreatic tumors Gastrinomas Insulinomas Glucagonomas VIPomas Somatostatinomas Pancreatic Polypeptide-Producing tumors

  17. Entero-pancreatic tumors • Prevalence ranges from 30-75% • Lesions tend to be multicentric • Micro/macroadenomas -> invasive -> metastaic carcinoma • As a result of the effective rx available for parathyroid & pituitary maifestations in MEN-1 the malignant potential of these entero-pancreatic lesions is now the primary life threatening manifestation of the syndrome.

  18. Gastrinoma • Most common – represent 50% of all entero-pancreatic tumors in MEN1 tend to be small & multiple lesions • MEN1 gastrinomas mostly in duodenum, 50% metastasized at Dx • Poor prognosis w/ pancreatic (not duodenal); mets; & higher gastrin level • Biochemical diagnosis incl: hypergastrinemia, mult peptic ulcers & hi gastric acid output • Imaging – octreotide scan, EGD U/S, CT/MRI & portal venous sampling MEDICAL TREATMENT: • PPI’s - Omeprazole

  19. Gastrinoma (cont) SURGICAL TREATMENT: • For solitary sporadic gastrinoma - complete resection • MEN1 gastrinomas freq mult/mets – controversial role of surgery • Intraop US • “Gastrinoma triangle” –pancreas/duodenum/CBD • Duodenotomy • Tumors head pancreas-enucleated • Tumors body/tail pancreas – distal pancreatectomy +- splenectomy • Liver mets- wedge resection

  20. Norton et al. 1999 NEJM

  21. Gastrinoma (cont) METASTATIC GASTRINOMA: • 25-90% of ZE patients • ChemoRx – streptozocin & 5 FU • Hepatic arterial chemoembolization • Octreotide • Interferon  • Aggressive debulking surgery

  22. Insulinoma • Pt p/w hypoglycemia after fast/exertion; sx improve w/ glucose intake & inappropriately elevated insulin • 90% solitary and benign • head, body and tail pancreas • Malignancy - size > 6cm or liver/nodal mets MEDICAL TREATMENT: • Control Sx prior to surgery • Frequent small CHO meals until operated on • Octreotide

  23. Insulinoma (cont) SURGICAL TREATMENT: • Mainstay • Precise identification w/ intraop ultrasound • Large malignant tumors or adjacent to vital structures - distal pancreatectomy or Whipple’s pancreaticoduodenectomy

  24. Insulinoma (cont) SURGERY FOR MALIGNANT INSULINOMA : • Curative • Whipple’s or subtotal pancreatectomy-splenectomy, excision of liver metastases • Palliation for metastatic disease • ChemoRx • Chemo-embolization • Alcohol injection, cryotherapy, radiofrequency ablation COMPLICATIONS of SURGICAL TREATMENT: • Abscess • Fistula • Pseudocyst • Wound infection

  25. Glucagonoma • Necrolytic migratory erythema • Hypoaminoacidaemia, Type II DM, muscle wasting, cachexia, DVT/PE • Tail of Pancreas most common site • Surgical removal is treatment of choice • However, 50-80% w/ mets at time of diagnosis • Optimize medical conditions, TPN, octreotide • ChemoRx - 5FU, streptozotocin, dacarbazine

  26. VIPoma • Vasoactive Intestinal Peptide tumors • Watery diarrhoea, hypokalaemia, achlorhydria (=WDHA), hypovolaemia, dehydration • 5-10 litres stool/day • correct dehydration • Surgical management w/ distal pancreatectomy curative

  27. Somatostatinoma • Duodenum/pancreas • Steatorrhoea, cholelithiasis, type II DM, hypochlorhydria • Medical problems – hyperglycaemia, malnutrition • Resect primary and debulk hepatic mets • Cholecystectomy

  28. Pancreatic Polypeptide-Producing tumors • Non-functioning • Malignant and large at time of Dx • Extrahepatic bile duct obstruction, GI bleeding, GI obstruction • Surgical resection • chemoRx for residual disease

  29. Other tumors CARCINOID: • 3% of MEN1 – bronchi, gi tract, pancreas, or thymus • Mostly asymptomatic no signs of carcinoid syndrome ADRENOCORTICAL LESIONS: • 20-40% MEN1 • Usually bilateral, hyperplastic, non-functional • No consensus on management of these lesions

  30. Other tumors BENIGN THYROID tumorS LIPOMAS • Cutaneous and visceral • Up to 1/3 of MEN1 patients • Tend not to recur once excised CNS EPENDYMOMAS COLLAGENOMAS, ANGIOFIBROMAS

  31. MULTIPLE ENDOCRINE NEOPLASIA: MEN I SYNDROME - Autosomal dominant disorder caused by loss of a tumor suppressor gene on chromosome 11. 1. Parathyroid hyperplasia or adenoma  Ca++ & renal calculi. 2. Pituitary adenoma: MC prolactinoma, also GH & ACTH (Cushing’s disease) producing tumors 3. Entero-pancreatic tumors  excessive secretion of: - gastrin peptic ulcers (Zollinger-Ellison syndrome), - insulin  hypoglycemia - serotonin (carcinoid syndrome) - VIP (vasoactive intestinal polypeptide) watery diarrhea

  32. References • Guideline for Diagnosis and Therapy of MEN Type 1 and Type 2 – Consensus. Journal of Clinical Endocrinology & Metabolism. 86(12):5658-71, 2001 Dec. • Gauger PG, Thompson NW. Early Surgical Intervention and strategy in patients with multiple endocrine Neoplasia Type 1. Best Practice and Research Clinical Endocrinology & Metabolism. 15(2):213-223, 2001 • Veldhuis et al. Therapeutic Controversy. Surgical Versus Medical Management of Multiple Endocrine Neoplasia Type 1. Journal of Clinical Endocrinology and Metabolism. 82(2):357-364 • Burgess et al. The outcome of subtotal thyroidectomy for treatment of hyperparathyroidism in MEN-1. Arch Surg 1998;133:126.

More Related